GILEAD SCIENCES, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
GILEAD SCIENCES, INC. (GILD) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets of $8.21 billion as of 2017-10-03, per its 10-K filed 2020-02-25.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets · last filed 2020-02-25
- 2017-10-03: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $8.21B; Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets as first filed $8.17B.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets as first filed |
|---|---|---|
| 2017-10-03 | $8.21B 10-K · filed 2020-02-25 | $8.17B 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |